BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37432054)

  • 1. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
    Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
    Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
    Zeng S; Zhang H; Zhang D; Hu X; Song L
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
    Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related gene
    Huang S; Cai C; Zhou K; Wang X; Wang X; Cen D; Weng G
    Aging (Albany NY); 2023 Nov; 15(21):12314-12329. PubMed ID: 37938155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma.
    Shen J; Wang L; Bi J
    BMC Cancer; 2023 Feb; 23(1):160. PubMed ID: 36797708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma.
    Jiang A; Ye J; Zhou Y; Zhu B; Lu J; Ge S; Qu L; Xiao J; Wang L; Cai C
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients.
    Zhang WT; Gong YM; Zhang CY; Pan JS; Huang T; Li YX
    Biomed Res Int; 2022; 2022():9196540. PubMed ID: 36105937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma.
    Wang H; Yang Z; He X; Guo F; Sun H; Xu S; Xu C; Wang Z; Wen H; Teng Z; Wang Y; Han Z
    BMC Cancer; 2023 Aug; 23(1):804. PubMed ID: 37641032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The core genes of cuproptosis assists in discerning prognostic and immunological traits of clear cell renal cell carcinoma.
    Chu B; Hong Z; Zheng X
    Front Oncol; 2022; 12():925411. PubMed ID: 36212447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenomedullin/FOXO3 enhances sunitinib resistance in clear cell renal cell carcinoma by inhibiting FDX1 expression and cuproptosis.
    Wang X; Jia JH; Zhang M; Meng QS; Yan BW; Ma ZY; Wang DB
    FASEB J; 2023 Oct; 37(10):e23143. PubMed ID: 37698353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated single-cell and bulk characterization of cuproptosis key regulator PDHB and association with tumor microenvironment infiltration in clear cell renal cell carcinoma.
    Wu J; Wang S; Liu Y; Zhang T; Wang X; Miao C
    Front Immunol; 2023; 14():1132661. PubMed ID: 37350959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
    Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.